ECOG Performance Status

The ECOG Performance Status (also known as the WHO or Zubrod performance status) is the most commonly used performance scale in oncology clinical trials and everyday clinical practice. Developed by the Eastern Cooperative Oncology Group in 1982, this simple 6-point scale (0-5) assesses a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability.

Performance status is one of the most important prognostic factors in oncology and is the single most requested baseline characteristic in clinical trial eligibility criteria. Approximately 95% of oncology clinical trials include performance status as an eligibility criterion, and the vast majority use the ECOG scale due to its simplicity and high inter-observer reliability compared to the more granular Karnofsky scale.

The ECOG scale assigns patients to one of six grades: Grade 0 (fully active, able to carry on all pre-disease performance without restriction), Grade 1 (restricted in physically strenuous activity but ambulatory and able to carry out light work), Grade 2 (ambulatory and capable of all self-care but unable to carry out work activities, up and about more than 50% of waking hours), Grade 3 (capable of only limited self-care, confined to bed or chair more than 50% of waking hours), Grade 4 (completely disabled, totally confined to bed or chair), and Grade 5 (dead).

In practice, the critical distinctions are between ECOG 0-1 (good performance status), ECOG 2 (borderline), and ECOG 3-4 (poor performance status). Patients with ECOG 0-1 are generally eligible for most treatments including aggressive chemotherapy regimens and clinical trials. ECOG 2 patients may be eligible for less toxic regimens. ECOG 3-4 patients are typically not candidates for active treatment and are often referred to palliative care.

The prognostic significance of ECOG performance status has been demonstrated across all major cancer types. In non-small cell lung cancer, for example, median survival ranges from approximately 9-12 months for ECOG 0-1 to only 3-4 months for ECOG 2, to weeks for ECOG 3-4. Similar patterns are observed in colorectal cancer, breast cancer, pancreatic cancer, and hematologic malignancies.

The ECOG scale is preferred in clinical trials because of its simplicity and reproducibility. Inter-observer agreement for ECOG is approximately 60-70% (kappa 0.50-0.65), which is acceptable for clinical use. Agreement is highest at the extremes (ECOG 0 and ECOG 4) and lowest at the intermediate levels (ECOG 1-2), where the clinical distinction can be subtle.